Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Albiglutide (Primary) ; Glimepiride; Metformin; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms HARMONY 3; HARMONY-3
  • Sponsors GlaxoSmithKline

Most Recent Events

  • 16 Sep 2016 Results of pooled analysis of four HARMONY programme trials (HARMONY-1, -2, -3 and -5) presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
  • 16 Sep 2016 Results of post-hoc pooled analysis from HARMONY 1-7 trials assessing the relationship between renal function and change in HbA 1c presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
  • 19 Sep 2014 Results at the end of 3 years presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top